2 enrolling by invitation. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Enrolling by invitation 2 |
| Phase 3 | 1 | Enrolling by invitation 1 |
Follow Glomerulonephritis, IGA: new trials by email Literature Review of Glomerulonephritis, IGA trials Research Report on Glomerulonephritis, IGA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept Atacicept 150 mg - IgA Nephropathy (IgAN), Renal and Urinary Disorders | Phase 2 | Enrolling by invitation | Vera Therapeutics, Inc. | 750 | 2024-12-01 | 2026-06-22 |
| Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) Sibeprenlimab 400 mg s.c. Q4weeks - Immunoglobulin A Nephropathy | Phase 2 / Phase 3 | Enrolling by invitation | Otsuka Pharmaceutical Development & Commercialization, Inc. | 600 | 2022-04-05 | 2026-05-05 |
Autoimmune Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Glomerulonephritis (2) · Immune System Diseases (2) · Kidney Diseases (2) · Male Urogenital Diseases (2) · Nephritis (2) · Urogenital Diseases (2) · Urologic Diseases (1)
TACI receptor-IgG Fc fragment fusion protein (1)
Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · Vera Therapeutics, Inc. (1)
United States (2) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Canada (1) · China (1) · Croatia (1) · Czechia (1) · France (1) · Germany (1) · Greece (1) · Hong Kong (1) · Hungary (1) · India (1)
Eric Michael, MD (1)